LexaGene develops on-site, automated genetic analyzers for rapid pathogen detection for human clinical diagnostics, veterinary diagnostics, food safety and more.
The MiQLab™ analyzer will transform how pathogens are detected at point-of-need and deliver results in approximately one hour.
21 September 2020 – LexaGene’s CEO Provides Video Message on Company’s Progress and Announces Appointment of Dr. Shelley Rankin to Company’s Scientific Advisory Board.
Innovation in the Making
Introducing LexaGene’s MiQLab automated genetic analyzer. Imagine a new way of testing on-site for multiple pathogens
at once that allows for open-access customized testing, can be used by nontechnical users, and returns reference-quality results in approximately one hour.
LexaGene on-site analyzer for COVID-19
LexaGene’s pathogen detection analyzer delivers sample-to-answer insight at the point-of-need for approximately 1-hour results. Read news release.
LexaGene Company Presentation
We are commercializing MiQLab genetic analyzer, the first ‘open-access’ analyzer for pathogen detection, allowing users to target multiple pathogens and return results in about an hour.
Forbes feature on LexaGene
Forbes profile on LexaGene’s technology: ‘It’s hard to imagine a startup better positioned to respond to the coronavirus pandemic than Beverly, Massachusetts-based LexaGene.’